SIMBOSPROST: Prevalence of metabolic syndrome and osteoporosis in prostate cancer patients treated with radiotherapy and androgen deprivation therapy: A multicentre, cross-sectional study.

Aim: To assess the prevalence of metabolic syndrome (MetS) and osteoporosis in patients with prostate cancer (PCa) treated with radical radiotherapy (RT) with or without androgen deprivation therapy (ADT).

Background: Worldwide, the prevalence of MetS is estimated to range from 20% to 25% of the adult population. However, prevalence rates are much higher in PCa patients (pts) who undergo ADT.

[Adjuvant radiotherapy after radical prostatectomy as preventive treatment for biochemical recurrence].

Adjuvant radiotherapy (RT) has proven to be more effective in patients at high risk of relapse than salvage RT when this relapse occurs. To optimize its use we must identify the subset of patients at greater risk of residual microscopic disease after surgery, since in them the likelihood of 5-10 year biochemical failure can reach 60%. There are many studies on the subject in which these factors are identified, which in general are: presence of positive margins and capsular or seminal vesicle involvement (T3a-b).